Teva, GSK Face Another Suit Over Generic Lamictal Deal

Law360, New York (October 26, 2012, 5:47 PM EDT) -- Teva Pharmaceutical Industries Ltd. and GlaxoSmithKline LLC were hit Thursday with another proposed class action alleging the companies manipulated a patent settlement to inflate the cost of epilepsy drug Lamictal or its generic equivalent.

The International Brotherhood of Electrical Workers Local 595 Health and Welfare Fund, the plaintiff in the current suit, says the companies' 2005 settlement inflated costs and delayed the availability of a generic version of the drug for years. The companies already face at least one other proposed class action over the deal....
To view the full article, register now.